Read
- Frenetic search for survivors as 91 feared dead in tornado-hit Oklahoma
|
- Israel fires back at Syria after gunshots at its troops
- Drop in U.S. underground water levels has accelerated -USGS
- Dollar firms as Fed suspense builds, shares off highs
|
- IRS officials back on Capitol Hill hot seat over targeting
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Tornado chasers
Storm chasers brave danger and debris as they try to capture photos of tornadoes' destructive power. Slideshow
Running while blind
Blind or visually impaired students compete in blind track and field tournament. Slideshow
Sponsored Links
FDA staff says Zogenix painkiller has abuse risks
(Reuters) - Drug reviewers said a painkiller developed by Zogenix Inc could possibly be abused more than currently available hydrocodone combination products.
Zogenix's painkiller Zohydro is a single-entity product containing hydrocodone -- a narcotic painkiller. Hydrocodone and oxycodone are often-abused drugs.
Combination hydrocodone drugs usually also contain acetaminophen, the active ingredient in common pain products such as Tylenol.
However, since an overdose of acetaminophen can cause liver damage, especially in patients on other acetaminophen medications, there is a requirement for painkillers without acetaminophen.
The reviewers said the expected higher levels of abuse with Zohydro were based on what has been observed for oxycodone products, according to briefing documents released by the U.S. Food and Drug Administration on Wednesday. (link.reuters.com/hux44t)
"The abuse ratio for oxycodone combination products was 24 emergency department visits per million tablets dispensed, compared with 85 visits for oxycodone single-entity ER products," the FDA reviewers said in the documents.
An independent panel of experts will advise the FDA and vote on the drug's safety, efficacy and approval on Friday.
Zogenix shares were down 6 percent at $2.39 in early trade on Wednesday on the Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Many lives have been already made more difficult with the Vicodin reformulation. Patients now get Norco, which is NOT as effective. It seems that the addicts are running the show while suffering patients are thrown under the bus again and again.
Follow Reuters